Author

Daniel J. George

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

Patients with chemotherapy‐ and androgen receptor pathway inhibitor (ARPI)‐naïve metastatic castration‐resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic...

D. George, J. Ivanova, M. Touya et al. · Cancer Medicine · 0 citations

Review Open access Sep 2026

Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone Therapy.

IMPORTANCE Cardiovascular disease (CVD) is a leading noncancer cause of death among patients with prostate cancer (PC). Population-based risk calculators do not account for treatment-related effects of androgen-deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPis), and they have not been validated...

A. Guha, Ana Barac, M. Ryan et al. · JCO Oncology Practice · 0 citations